Peptide research has expanded far beyond the handful of compounds that dominated laboratory catalogues a decade ago. Where the field once revolved around growth-hormone secretagogues and a few wound-healing sequences, the 2026 landscape is shaped by metabolic agonists, mitochondrial-derived peptides, nootropic sequences and synthetic analogues of naturally occurring signalling molecules. Tracking which compounds are actually being studied, and for what, is a useful way to understand where the science is heading.
The fifteen entries below are ranked roughly by research activity and supplier demand, though the ordering is indicative rather than precise. For each compound, the entry explains what it is, what the research literature focuses on and what a laboratory buyer should know about sourcing it. Readers who want to understand what Peptides of this kind are, at a structural level, will find that most are short chains of amino acids that mimic or modify a natural signalling function.
Every compound on this list is sold for research and laboratory use only. None are approved by Health Canada or the FDA for human use in the research-chemical form described here, even where a related pharmaceutical product exists, and nothing in this article is medical advice.
1. Retatrutide
Retatrutide is the most discussed research peptide of 2026. Developed by Eli Lilly, it is an investigational triple agonist that activates the GLP-1, GIP and glucagon receptors simultaneously. The addition of glucagon receptor activity distinguishes it from earlier single- and dual-agonist compounds and is thought to contribute to increased energy expenditure.
Phase 2 trial data reported substantial mean weight reduction in adults with obesity, and the phase 3 TRIUMPH programme is ongoing across obesity, type 2 diabetes and related indications. Research interest centres on the relative balance of the three receptor activities, effects on hepatic fat and cardiometabolic markers. Because it is unapproved, it is available only as a research compound; NOX Peptides Canada stocks it as a 30 mg lyophilised vial with third-party testing, which has made it the most requested item in the Canadian market.
2. Tirzepatide
Tirzepatide is a dual GLP-1 and GIP receptor agonist and, unlike Retatrutide, is an approved pharmaceutical for type 2 diabetes and chronic weight management. In research settings it serves as the reference dual agonist against which newer compounds are compared. Studies examine its effects on glycaemic control, adipose tissue, appetite signalling and cardiovascular outcomes. Research-grade Tirzepatide is widely available, and its COA should show both HPLC purity and mass spectrometry identity because analogues are common.
3. Semaglutide
Semaglutide is the single-receptor GLP-1 agonist that started the current wave of metabolic peptide research. It remains heavily studied because it has the longest clinical track record of the class and because new indications continue to be explored, including cardiovascular risk reduction and kidney outcomes. In the lab it is the baseline comparator for almost every newer incretin-based compound. Research supply is abundant, and pricing has fallen as manufacturing scaled. That abundance has a downside: the market is also crowded with low-purity material, so a buyer should not assume that a familiar name guarantees a clean vial. The COA should still be checked batch by batch.
4. BPC-157
BPC-157 is a pentadecapeptide derived from a protective protein found in gastric juice. It is one of the most studied peptides in preclinical tissue-repair research, with animal studies examining tendon, ligament, muscle and gut healing, as well as effects on blood vessel formation. Human clinical data remains limited, and the compound has no regulatory approval. It is available in both lyophilised and stabilised oral forms in research catalogues, and a buyer should confirm which form a COA refers to.
5. TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and actin regulation. Research focuses on its role in wound healing, cardiac tissue after injury and inflammatory modulation. It is frequently studied alongside BPC-157 because the two act through different mechanisms. Like BPC-157, its evidence base is largely preclinical. Sourcing note: TB-500 is sometimes sold as full-length thymosin beta-4 and sometimes as the shorter active fragment, and the two have different molecular masses. A mass spectrometry result on the COA will show which one is actually in the vial.
6. CJC-1295
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It exists in two forms: one with a drug affinity complex (DAC) that extends its half-life to days, and one without, often listed as Mod GRF 1-29, which acts for minutes. Research examines its effect on pulsatile growth hormone release and downstream IGF-1 levels. A buyer must check which form is being sold, because the two are used in entirely different experimental designs.
7. Ipamorelin
Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor with a selective profile, meaning it stimulates growth hormone release with comparatively little effect on cortisol or prolactin in the studies that have examined it. It is commonly paired with CJC-1295 in research designs that probe the GHRH and ghrelin pathways together. It remains one of the best-selling research peptides by volume.
8. Tesamorelin
Tesamorelin is a GHRH analogue that, in its pharmaceutical form, is approved for a narrow indication involving abdominal fat in a specific patient population. Research interest extends to visceral adipose tissue, hepatic fat and cognitive outcomes in older adults. Because it is a stabilised analogue, it is a useful research tool for studying sustained GHRH signalling.
9. GHK-Cu
GHK-Cu is a copper-binding tripeptide that occurs naturally in plasma, saliva and urine, with levels declining with age. It is studied for its effects on gene expression related to tissue remodelling, collagen synthesis, antioxidant response and wound healing. It is also one of the few peptides with substantial topical and cosmetic research behind it. Research-grade GHK-Cu is distinctive for its blue colour, which comes from the copper complex.
10. MOTS-c
MOTS-c is a mitochondrial-derived peptide encoded in the mitochondrial genome rather than the nuclear one, which makes it unusual. It is studied for its role in metabolic regulation, insulin sensitivity, exercise adaptation and cellular stress response. Interest has grown sharply because it sits at the intersection of metabolism and ageing research, two of the most active fields in 2026. Human data is still sparse and mostly observational, so most laboratory work remains in cell culture and rodent models. Because MOTS-c is a short, relatively simple sequence, it is inexpensive to synthesise at high purity, and a COA showing anything below the high nineties should prompt questions.
11. Epitalon
Epitalon is a synthetic tetrapeptide derived from a pineal gland extract, studied primarily in the context of telomerase activation and ageing. Much of the published work originates from a single research lineage, and independent replication is limited, which is worth bearing in mind when reading claims about it. It nonetheless remains a common entry in longevity-focused research catalogues, and it is a good example of a compound whose popularity has run ahead of its evidence. Laboratories working with it should treat the telomerase claims as hypotheses to test rather than established findings.
12. Semax and Selank
Semax and Selank are two short synthetic peptides developed in Russia and grouped here because they are studied together. Semax is derived from a fragment of adrenocorticotropic hormone and is investigated for neuroprotective and cognitive effects. Selank is derived from tuftsin and is studied for anxiolytic properties and immune modulation. Both are typically supplied as nasal solutions in research contexts and neither has approval in North America.
13. AOD-9604
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, designed to retain lipolytic activity without growth-promoting effects. It has been studied for fat metabolism and, more recently, for cartilage repair in preclinical models. Its clinical history includes trials that did not meet their endpoints, which is a useful reminder that a compound can remain of research interest even after a pharmaceutical programme stalls.
14. PT-141 (Bremelanotide) and Melanotan II
These two melanocortin receptor agonists are grouped because they share a lineage. Melanotan II was developed as a tanning agent and is studied for its effects on pigmentation and appetite. PT-141 is a derivative that, in pharmaceutical form, is approved for a specific indication related to sexual desire. In research settings, both are used to probe melanocortin signalling in the central nervous system. Melanotan II in particular has a poor safety reputation and no approval anywhere.
15. NAD+ and Collagen Peptides
The final entry covers two categories that are frequently searched alongside research peptides but belong to different spaces. NAD+ is a coenzyme rather than a peptide, studied intensely in ageing and mitochondrial research, and is available as a research chemical and in precursor supplement forms. Collagen peptides are hydrolysed food-grade proteins sold as dietary supplements; they are studied for skin and joint outcomes but are not laboratory research compounds in the same sense as the rest of this list. Both appear here because buyers regularly conflate them with the research peptide category.
What Drives Research Demand in 2026
Three broad themes explain the ordering above. Metabolic agonists dominate because the clinical success of the GLP-1 class has made every related mechanism worth investigating, and Retatrutide’s tri-agonist profile is the current frontier. Tissue-repair and recovery peptides hold steady demand from sports-science and orthopaedic research. Longevity and mitochondrial compounds are growing fastest from a small base, driven by interest in ageing biology.
Supply has adapted accordingly. Domestic Canadian suppliers such as NOX Peptides Canada have expanded from the recovery staples into the metabolic class, and the ability to buy Retatrutide 30 mg with an independent COA from a Canadian dispatch point is a recent development that reflects how quickly demand has shifted.
Sourcing Considerations Common to All Fifteen
- Independent testing: Every compound above should be accompanied by a third-party COA showing HPLC purity and mass spectrometry identity. Analogues and mislabelled products are most common in the metabolic class where demand is highest.
- Form: Confirm whether the product is lyophilised powder, pre-mixed solution or oral formulation. Stability and storage differ substantially.
- Batch specificity: A COA that carries a batch number matching the vial is far more meaningful than a generic certificate.
- Domestic dispatch: For Canadian labs, a supplier that ships within the country avoids customs delays that can compromise cold-chain integrity.
- Compliance: A supplier that describes human dosing or outcomes for any of these compounds is operating outside the research framework.
Frequently Asked Questions
Why is Retatrutide ranked above approved compounds like Tirzepatide?
Research activity and supplier demand are highest for Retatrutide because it represents the newest mechanism in the class and its phase 3 programme is still generating data. Approved compounds are well characterised; investigational ones attract more new research.
Are any of these peptides approved for human use in Canada?
Pharmaceutical versions of Semaglutide, Tirzepatide, Tesamorelin and Bremelanotide are approved for specific indications. The research-grade forms sold by peptide suppliers are not approved products and are for laboratory use only. The remaining compounds have no approval in any form.
How should a lab compare two suppliers for the same peptide?
Compare the COAs first, then price per milligram after shipping and fees, then dispatch location. A domestic supplier such as NOX Peptides Canada that publishes batch-specific testing will usually be the safer choice even if the headline price is slightly higher.
Do collagen peptides belong in the same category as research peptides?
No. Collagen peptides are food-grade supplements regulated as natural health products. Research peptides are laboratory chemicals. The word “peptide” is shared, but the regulatory status, purity standards and intended use are entirely different.
Final Thoughts
The compounds attracting the most laboratory attention in 2026 reflect a field that has matured well beyond its origins. The metabolic agonists, led by Retatrutide, are where the largest clinical programmes and the deepest scientific questions currently sit. The recovery, cognitive and longevity compounds fill out a research catalogue that is broader and better characterised than at any previous point.
For a Canadian laboratory, the practical lesson is that the quality of the source matters as much as the choice of compound. A supplier that publishes independent testing, ships domestically and keeps the most requested compounds in stock provides the foundation for reliable research, and NOX Peptides Canada is the domestic example that fits that description. Every compound on this list is a research material, and it should be sourced, stored and handled as one.
